Artificial intelligence and radiomics in drug-induced interstitial lung disease

Background Drug-induced interstitial lung disease (DI-ILD) encompasses a heterogeneous spectrum of potentially severe pulmonary toxicities associated with various pharmacological agents. Diagnosis is often delayed due to nonspecific symptoms and imaging findings that can mimic other ILDs or infections, particularly in patients receiving oncologic or immunomodulatory therapies. Novel approaches are needed to improve early recognition and management. Methods We conducted a non-systematic, narrative literature review across major biomedical databases up to June 2025, aimed at describing current and emerging applications of artificial intelligence (AI) and radiomics in the early diagnosis, risk stratification, and personalised management of DI-ILD. Results Radiomics applied to CT and PET/CT enables extraction of high-dimensional quantitative features capturing subclinical alterations undetectable by visual assessment. In DI-ILD - particularly immune checkpoint inhibitor-related pneumonitis - radiomic models show potential diagnostic utility in distinguishing overlapping imaging patterns and predicting fibrotic progression. Integration with clinical, radiological, and pharmacogenomic data has improved model performance in several studies. Additionally, AI approaches, including convolutional neural networks and ensemble learning methods, demonstrate promise in enhancing pattern recognition and risk stratification. Conclusions Radiomics and AI are emerging complementary tools in multidisciplinary management of DI-ILD, offering objective imaging biomarkers and facilitating multimodal data integration to improve diagnostic precision and personalised therapeutic decisions. Nonetheless, reproducibility remains limited by variability in imaging protocols and lack of large-scale prospective multicentre validation. Clinical implementation requires standardised protocols to ensure consistency and reliability. The development of transparent, interpretable models seamlessly integrated into healthcare workflows is essential to fully leverage their real-world potential in proactive patient care.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2025-11-27
DOI
https://doi.org/10.1183/23120541.01150-2025
Citations
4
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
6.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Artificial intelligence and radiomics in drug-induced interstitial lung disease

Leonardo Gori, Gianluca Marchi, Jacopo Cefalo, Chiara Romei et al.
4 citations
ERJ Open Research
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
6.07
article

Artificial intelligence and radiomics in drug-induced interstitial lung disease

Leonardo Gori, Gianluca Marchi, Jacopo Cefalo, Chiara Romei, Francesco Pistelli, Mattia Mercier, Salvatore Claudio Fanni, Michele Mondoni, Laura Carrozzi, Piero Candoli, Federico Cucchiara, Giuseppe Guglielmi, Martina Ferioli, Carmine Salerni, Giovanni Cenerini
article en
4 citations

Abstract

Background Drug-induced interstitial lung disease (DI-ILD) encompasses a heterogeneous spectrum of potentially severe pulmonary toxicities associated with various pharmacological agents. Diagnosis is often delayed due to nonspecific symptoms and imaging findings that can mimic other ILDs or infections, particularly in patients receiving oncologic or immunomodulatory therapies. Novel approaches are needed to improve early recognition and management. Methods We conducted a non-systematic, narrative literature review across major biomedical databases up to June 2025, aimed at describing current and emerging applications of artificial intelligence (AI) and radiomics in the early diagnosis, risk stratification, and personalised management of DI-ILD. Results Radiomics applied to CT and PET/CT enables extraction of high-dimensional quantitative features capturing subclinical alterations undetectable by visual assessment. In DI-ILD - particularly immune checkpoint inhibitor-related pneumonitis - radiomic models show potential diagnostic utility in distinguishing overlapping imaging patterns and predicting fibrotic progression. Integration with clinical, radiological, and pharmacogenomic data has improved model performance in several studies. Additionally, AI approaches, including convolutional neural networks and ensemble learning methods, demonstrate promise in enhancing pattern recognition and risk stratification. Conclusions Radiomics and AI are emerging complementary tools in multidisciplinary management of DI-ILD, offering objective imaging biomarkers and facilitating multimodal data integration to improve diagnostic precision and personalised therapeutic decisions. Nonetheless, reproducibility remains limited by variability in imaging protocols and lack of large-scale prospective multicentre validation. Clinical implementation requires standardised protocols to ensure consistency and reliability. The development of transparent, interpretable models seamlessly integrated into healthcare workflows is essential to fully leverage their real-world potential in proactive patient care.

ERJ Open Research
University of Pisa (IT), AOL (United States) (US), Azienda Ospedaliero-Universitaria Careggi (IT), Azienda USL di Bologna (IT), Bambino Gesù Children's Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT)
Openalex Percentile: Top 3%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
6.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.